FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385294> ?p ?o ?g. }

• W4308385294 abstract "<h3>Background</h3> Immune checkpoint inhibitors (ICI) have changed the cancer treatment paradigm, yet significant unmet need remains. Clinical data demonstrates increased antigen presentation diversity, genomic instability, tumor mutational burden and HLA diversity are all factors that improve clinical response to ICI.^1,2,3 Further, the effectiveness of ICI is limited by the permanent exhaustion of pre-existing cytotoxic T cells, caused by chronic cancer antigen stimulation.⁴ Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims peptides loaded into classical and nonclassical MHC Class I.⁵ In cancer, knockout or inhibition of ERAP1 changes a proportion of the antigen repertoire, generating and up-regulating cancer antigens.^6,7 This leads to the activation of de novo anti-tumor T cell responses, causing tumour growth inhibition and bypassing a key resistance mechanism in immuno-oncology (IO), T cell exhaustion. We report the preclinical development, characterisation and mechanistic analysis of the first-in-class ERAP1 inhibitor, GRWD5769. <h3>Methods</h3> Immunopeptidomics was used to assess the impact of ERAP1 inhibition on the cancer antigen repertoire, thus determine proof of mechanism. T cell receptor (TCR) repertoire sequencing, RNAseq and immunohistochemistry established the ability of ERAP1 inhibition to drive a differentiated T cell response in syngeneic mouse models and primary human immune cell co-cultures. <h3>Results</h3> Extensive analysis of the immunopeptidomes of diverse cancer cell lines robustly showed that GRWD5769 modulates the cancer-related antigen repertoire across genotypes and cancer-type backgrounds. Novel or upregulated neoantigens generated by ERAP1 inhibition are conserved across cancer cell types and genetic backgrounds. ERAP1 inhibition diversified the TCR repertoire, up-regulated prognostic immune gene markers in the tumor, including markers for recently activated (thus non-exhausted) T cells, and drove infiltration of T cells into syngeneic mouse model tumours. ERAP1 inhibition is efficacious across syngeneic models, including different mouse strains. Importantly, the effects of ERAP1 inhibition on the T cell response correlate with efficacy. Further, ex vivo human T cell co-cultures demonstrate that novel and upregulated neoantigens generated by ERAP1 inhibition drive tumour cell killing. <h3>Conclusions</h3> Grey Wolf Therapeutics’ first-in-class, ERAP1 inhibitor clinical candidate, GRWD5769, drives novel anti-tumor T cell responses through neoantigen creation, circumventing T cell exhaustion, a key resistance mechanism in IO. GRWD5769 has completed GLP toxicology studies, has a very good safety profile and clear path forward to first patient dosed. Extensive biomarker development has resulted in development of proof of mechanism and proof of principle biomarkers that will be used to establish the activity and efficacy of GRWD5769 in patients in 2023. <h3>References</h3> Rizvi N, Hellmann MD, Snyder A, <i>et al</i>. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. <i>Science</i>. 2015;<b>348</b>(6230):124–128. Chowell D, uc G T Morris LGT,2 3, Grigg CM <i>et al</i>. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> 2018;<b>359</b> (6375):582–587 Chowell D, Chirag Krishna, Federica Pierini et al Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> 2019;<b>25</b>(11):1715–1720 Oliveira G, Stromhaug K, Klaeger S, <i>et al</i>. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> 2021;<b>596</b>:119–125 Shastri N, Nagarajan N, Lind KC, <i>et al</i>. Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. <i>Curr Opin Immunol</i>. 2014;<b>26</b>:123–127. James E, Bailey I, Sugiyarto G, <i>et al</i>. Induction of protective antitumor immunity through attenuation of ERAAP function. <i>J Immunol</i>. 2013;<b>190</b>(11):5839–5846. Manguso RT, Pope, HW, MD Zimmer et al In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. <i>Nature</i> 2017;<b>547</b>(7664):413–418" @default.
• W4308385294 created "2022-11-11" @default.
• W4308385294 creator A5013159491 @default.
• W4308385294 creator A5015292930 @default.
• W4308385294 creator A5025036243 @default.
• W4308385294 creator A5029747131 @default.
• W4308385294 creator A5032039751 @default.
• W4308385294 creator A5039313243 @default.
• W4308385294 creator A5053708916 @default.
• W4308385294 creator A5053869245 @default.
• W4308385294 creator A5056261455 @default.
• W4308385294 creator A5056479725 @default.
• W4308385294 creator A5062898783 @default.
• W4308385294 creator A5068519558 @default.
• W4308385294 creator A5083126876 @default.
• W4308385294 creator A5087347737 @default.
• W4308385294 creator A5090536136 @default.
• W4308385294 date "2022-11-01" @default.
• W4308385294 modified "2023-10-18" @default.
• W4308385294 title "1131 GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses" @default.
• W4308385294 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1131" @default.
• W4308385294 hasPublicationYear "2022" @default.
• W4308385294 type Work @default.
• W4308385294 citedByCount "0" @default.
• W4308385294 crossrefType "proceedings-article" @default.
• W4308385294 hasAuthorship W4308385294A5013159491 @default.
• W4308385294 hasAuthorship W4308385294A5015292930 @default.
• W4308385294 hasAuthorship W4308385294A5025036243 @default.
• W4308385294 hasAuthorship W4308385294A5029747131 @default.
• W4308385294 hasAuthorship W4308385294A5032039751 @default.
• W4308385294 hasAuthorship W4308385294A5039313243 @default.
• W4308385294 hasAuthorship W4308385294A5053708916 @default.
• W4308385294 hasAuthorship W4308385294A5053869245 @default.
• W4308385294 hasAuthorship W4308385294A5056261455 @default.
• W4308385294 hasAuthorship W4308385294A5056479725 @default.
• W4308385294 hasAuthorship W4308385294A5062898783 @default.
• W4308385294 hasAuthorship W4308385294A5068519558 @default.
• W4308385294 hasAuthorship W4308385294A5083126876 @default.
• W4308385294 hasAuthorship W4308385294A5087347737 @default.
• W4308385294 hasAuthorship W4308385294A5090536136 @default.
• W4308385294 hasBestOaLocation W43083852941 @default.
• W4308385294 hasConcept C121608353 @default.
• W4308385294 hasConcept C147483822 @default.
• W4308385294 hasConcept C154317977 @default.
• W4308385294 hasConcept C19317047 @default.
• W4308385294 hasConcept C202751555 @default.
• W4308385294 hasConcept C203014093 @default.
• W4308385294 hasConcept C207936829 @default.
• W4308385294 hasConcept C2776090121 @default.
• W4308385294 hasConcept C502942594 @default.
• W4308385294 hasConcept C54355233 @default.
• W4308385294 hasConcept C86803240 @default.
• W4308385294 hasConcept C8891405 @default.
• W4308385294 hasConcept C96232424 @default.
• W4308385294 hasConceptScore W4308385294C121608353 @default.
• W4308385294 hasConceptScore W4308385294C147483822 @default.
• W4308385294 hasConceptScore W4308385294C154317977 @default.
• W4308385294 hasConceptScore W4308385294C19317047 @default.
• W4308385294 hasConceptScore W4308385294C202751555 @default.
• W4308385294 hasConceptScore W4308385294C203014093 @default.
• W4308385294 hasConceptScore W4308385294C207936829 @default.
• W4308385294 hasConceptScore W4308385294C2776090121 @default.
• W4308385294 hasConceptScore W4308385294C502942594 @default.
• W4308385294 hasConceptScore W4308385294C54355233 @default.
• W4308385294 hasConceptScore W4308385294C86803240 @default.
• W4308385294 hasConceptScore W4308385294C8891405 @default.
• W4308385294 hasConceptScore W4308385294C96232424 @default.
• W4308385294 hasLocation W43083852941 @default.
• W4308385294 hasOpenAccess W4308385294 @default.
• W4308385294 hasPrimaryLocation W43083852941 @default.
• W4308385294 hasRelatedWork W1976062079 @default.
• W4308385294 hasRelatedWork W1993875521 @default.
• W4308385294 hasRelatedWork W2001055320 @default.
• W4308385294 hasRelatedWork W2008949385 @default.
• W4308385294 hasRelatedWork W2016887421 @default.
• W4308385294 hasRelatedWork W2026564383 @default.
• W4308385294 hasRelatedWork W2031356189 @default.
• W4308385294 hasRelatedWork W2220102944 @default.
• W4308385294 hasRelatedWork W2409441623 @default.
• W4308385294 hasRelatedWork W4283731173 @default.
• W4308385294 isParatext "false" @default.
• W4308385294 isRetracted "false" @default.
• W4308385294 workType "article" @default.